HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of two dosages of subcutaneous low molecular weight heparin (Parnaparin) and of unfractionated heparin on fibrin formation and lipolysis in acute myocardial infarction.

Abstract
Although low molecular weight heparins (LMWH) have been extensively investigated for the prophylaxis and treatment of venous thromboembolism in surgical environments, few data in acute myocardial infarction are available in the literature. In this study two dosages of a new LMWH, Parnaparin, and unfractionated heparin (UF) were investigated in 50 pts with acute myocardial infarction. 20 pts received UF (15.000 units, three subcutaneous injections, Group 1), 20 pts received Parnaparin (6.400 units, single injection, Group 2) and 10 pts received a higher dose of Parnaparin (12.800 units, single injection, Group 3). Similar fibrinopeptide A (FpA) levels were observed in Group 1 and Group 2. In Group 3 the dosage of Parnaparin resulted in a significant prolongation of the APTT and in lower FpA levels. Fibrin formation was decreased by Parnaparin in a concentration-dependent way, according to both the anti-Xa activity and the APTT ratio. Parnaparin did not result in a significant increase in free fatty acid concentration, in comparison with UF. Thus, Parnaparin may offer the advantage of a single subcutaneous injection in patients with acute myocardial infarction.
AuthorsG Melandri, A Branzi, F Semprini, V Cervi, B Magnani
JournalThrombosis research (Thromb Res) Vol. 66 Issue 2-3 Pg. 141-50 (May 01 1992) ISSN: 0049-3848 [Print] United States
PMID1329251 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Factor Xa Inhibitors
  • Heparin, Low-Molecular-Weight
  • Fibrin
  • Heparin
  • parnaparin
Topics
  • Aged
  • Dose-Response Relationship, Drug
  • Factor Xa Inhibitors
  • Female
  • Fibrin (biosynthesis)
  • Heparin (pharmacology, therapeutic use)
  • Heparin, Low-Molecular-Weight (administration & dosage, pharmacology, therapeutic use)
  • Humans
  • Injections, Subcutaneous
  • Lipolysis (drug effects)
  • Male
  • Middle Aged
  • Myocardial Infarction (blood, drug therapy)
  • Partial Thromboplastin Time

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: